E
Elliott M. Antman
Researcher at Brigham and Women's Hospital
Publications - 738
Citations - 187175
Elliott M. Antman is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 161, co-authored 716 publications receiving 179462 citations. Previous affiliations of Elliott M. Antman include Duke University & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
Acute ST-segment elevation myocardial infarction and prior stroke: An analysis from the Magnesium in Coronaries (MAGIC) trial ☆
Howard A. Cooper,Michael J. Domanski,Yves Rosenberg,James E. Norman,Judith H. Scott,Susan F. Assmann,Sonja M. McKinlay,Judith S. Hochman,Elliott M. Antman +8 more
TL;DR: Patients with prior stroke who present with STEMI are at very high risk for short-term morbidity and mortality and Aggressive treatment of these patients appears warranted.
Journal ArticleDOI
Heart-type fatty acid binding protein as a marker of reperfusion after thrombolytic therapy.
James A. de Lemos,Elliott M. Antman,David A. Morrow,Joan Llevadot,Robert P. Giugliano,Stephanie Coulter,Kristin C Schuhwerk,Shake Arslanian,Carolyn H. McCabe,C. Michael Gibson,Nader Rifai +10 more
TL;DR: Successful reperfusion can be detected within the first 60 min after thrombolysis with either H-FABP or myoglobin.
Journal ArticleDOI
Enoxaparin in unstable angina/non-ST-segment elevation myocardial infarction: treatment benefits in prespecified subgroups.
TL;DR: Evidence suggesting that enoxaparin administered subcutaneously twice daily may be considered as an alternative to intravenous UFH in the acute treatment of a broad range of patients with unstable coronary artery disease is reinforced.
Journal ArticleDOI
Nitroglycerine/N-acetylcysteine in the management of unstable angina pectoris
John D. Horowitz,C A Henry,M L Syrjanen,William J Louis,R D Fish,Elliott M. Antman,Thomas W. Smith +6 more
TL;DR: Combined treatment with NTG and NAC in patients with unstable angina pectoris may augment the clinical efficacy of NTG, largely by reducing the incidence of acute myocardial infarction, but the high incidence of severe hypotension suggests that this regimen should be used with some caution.
Journal ArticleDOI
Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome
Benjamin M. Scirica,Brian A. Bergmark,David A. Morrow,Elliott M. Antman,Marc P. Bonaca,Sabina A. Murphy,Marc S. Sabatine,Eugene Braunwald,Stephen D. Wiviott +8 more
TL;DR: In patients undergoing PCI for ACS, spontaneous events predominate after 30 days, with the later-phase cardiovascular benefit of potent dual antiplatelet therapy driven largely by reducing de novo atherothrombotic ischemic events.